Pulmonary vascular disease associated with schistosomiasis

Expert Review of Anti-Infective Therapy

Volumn 8, Issue 12, 2010, Pages 1467-1473

  Kolosionek, Ewa ^a,b   Crosby, Alexi ^b,c   Harhay, Michael O ^d   Morrell, Nicholas ^b,c   Butrous, Ghazwan ^a,b  

^a UNIVERSITY OF KENT   (United Kingdom)

^b Pulmonary Vascular Research Institute   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

inflammation; pulmonary hypertension; schistosomiasis; vascular remodeling

Indexed keywords

BOSENTAN; CD45 ANTIGEN; CD68 ANTIGEN; ELASTASE INHIBITOR; ILOPROST; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 5; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE V INHIBITOR; PRAZIQUANTEL; PROSTACYCLIN; PROTEIN TYROSINE KINASE INHIBITOR; RESISTIN; TUMOR NECROSIS FACTOR ALPHA; UNIPROST;

ACUTE DISEASE; B LYMPHOCYTE; CHRONIC DISEASE; DISEASE ASSOCIATION; HUMAN; IMMUNE RESPONSE; INFLAMMATION; MAST CELL; NONHUMAN; PATHOGENESIS; PREVALENCE; PULMONARY HYPERTENSION; PULMONARY VASCULAR DISEASE; REVIEW; SCHISTOSOMA HEMATOBIUM; SCHISTOSOMA JAPONICUM; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS; SCHISTOSOMIASIS HAEMATOBIA; SCHISTOSOMIASIS JAPONICA; SCHISTOSOMIASIS MANSONI; T LYMPHOCYTE;

ANIMALS; FEMALE; HUMANS; HYPERTENSION, PORTAL; HYPERTENSION, PULMONARY; INFLAMMATION; LUNG; MALE; PRAZIQUANTEL; SCHISTOSOMA; SCHISTOSOMIASIS;

EID: 78650222840     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.10.124     Document Type: Review

References (66)

1. Alpert JS, Irwin RS, Dalen JE. Pulmonary hypertension. Curr. Probl. Cardiol. 5, 1-39 (1981).
2. Chitsulo L, Engels D, Montresor A, Savioli L. The global status of schistosomiasis and its control. Acta Trop. 77, 41-51 (2000).
3. King CH. Parasites and poverty: the case of schistosomiasis. Acta Trop. 113, 95-104 (2010).
4. Ross AG, Bartley PB, Sleigh AC et al. Schistosomiasis. N. Engl. J. Med. 346, 1212-1220 (2002).
5. Warren KS. Experimental pulmonary schistosomiasis. Trans. R. Soc. Trop. Med. Hyg. 58, 228-233 (1964).
6. Rollinson D. A wake up call for urinary schistosomiasis: reconciling research effort with public health importance. Parasitology 136, 1593-1610 (2009).
7. Steinmann P, Keiser J, Bos R, Tanner M, Utzinger J. Schistosomiasis and water resources development: systematic review, meta-analysis, and estimates of people at risk. Lancet Infect. Dis. 6, 411-425 (2006).
8. Schwartz E. Pulmonary schistosomiasis. Clin. Chest Med. 23, 433-443 (2002).
9. Lapa M, Dias B, Jardim C et al. Cardiopulmonary manifestations of hepatosplenic schistosomiasis. Circulation 119, 1518-1523 (2009).
10. Leshem E, Maor Y, Meltzer E, Assous M, Schwartz E. Acute schistosomiasis outbreak: clinical features and economic impact. Clin. Infect. Dis. 47, 1499-1506 (2008).
11. Leshem E, Meltzer E, Marva E, Schwartz E. Travel-related schistosomiasis acquired in Laos. Emerging Infect. Dis. 15, 1823-1826 (2009).
12. Schwartz E, Rozenman J, Perelman M. Pulmonary manifestations of early schistosome infection among nonimmune travelers. Am. J. Med. 109, 718-722 (2000).
13. Graham BB, Bandeira AP, Morrell NW, Butrous G, Tuder RM. Schistosomiasis-associated pulmonary hypertension: pulmonary vascular disease: the global perspective. Chest 137, 20S-29S (2010).
14. de Jesus AR, Silva A, Santana LB et al. Clinical and immunologic evaluation of 31 patients with acute Schistosomiasis mansoni. J. Infect. Dis. 185, 98-105 (2002).
15. Cheever AW, Lenzi JA, Lenzi HL, Andrade ZA. Experimental models of Schistosomiasis mansoni infection. Mem. Inst. Oswaldo Cruz 97, 917-940 (2002).
16. Crosby A, Jones FM, Southwood M et al. Pulmonary vascular remodeling correlates with lung eggs and cytokines in murine schistosomiasis. Am. J. Respir. Crit. Care Med. 181, 279-288 (2010).
17. File S. Interaction of schistosome eggs with vascular endothelium. J. Parasitol. 81, 234-238 (1995).
18. Olds GR, Mahmoud AA. Role of host granulomatous response in murine Schistosomiasis mansoni. Eosinophil-mediated destruction of eggs. J. Clin. Invest. 66, 1191-1199 (1980).
19. Peterson W P, von Lichtenberg F. Studies on granuloma formation. IV. In vivo antigenicity of schistosome egg antigen in lung tissue. J. Immunol. 95, 959-965 (1965).
20. von Lichtenberg F, Byram JE. Pulmonary cell reactions in natural and acquired host resistance to Schistosoma mansoni. Am. J. Trop. Med. Hyg. 29, 1286-1300 (1980).
21. Graham BB, Mentink-Kane MM, El-Haddad H et al. Schistosomiasis-induced experimental pulmonary hypertension: role of interleukin-13 signaling. Am. J. Pathol. 177, 1549-1561 (2010).
22. Geiger SM, Massara CL, Bethony J, Soboslay PT, Carvalho OS, Correa-Oliveira R. Cellular responses and cytokine profles in Ascaris lumbricoides and Trichuris trichiura infected patients. Parasite Immunol. 24, 499-509 (2002).
23. Silveira-Lemos D, Teixeira-Carvalho A, Martins-Filho OA et al. Eosinophil activation status, cytokines and liver fbrosis in Schistosomiasis mansoni infected patients. Acta Trop. 108, 150-159 (2008).
24. Wynn TA, Thompson RW, Cheever AW, Mentink-Kane MM. Immunopathogenesis of schistosomiasis. Immunol. Rev. 201, 156-167 (2004).
25. Mentink-Kane MM, Cheever AW, Thompson RW et al. IL-13 receptor a 2 down-modulates granulomatous infammation and prolongs host survival in schistosomiasis. Proc. Natl Acad. Sci. USA 101, 586-590 (2004).
26. McHugh SM, Coulson PS, Wilson RA. Pathologically induced alterations in the dimensions of the hepatic portal vasculature of mice infected with Schistosoma mansoni. Parasitology 94(Pt 1), 69-80 (1987).
27. Andrade ZA, Andrade SG. Pathogenesis of schistosomal pulmonary arteritis. Am. J. Trop. Med. Hyg. 19, 305-310 (1970).
28. Wunschmann D, Ribas E. [Chronic cor pulmonale due to granulomatous and obliterating pulmonary arteritis caused by schistosomiasis]. Zentralbl. Allg. Pathol. 135, 241-247 (1989).
29. Sadigursky M, Andrade ZA. Pulmonary changes in schistosomal cor pulmonale. Am. J. Trop. Med. Hyg. 31, 779-784 (1982).
30. Clark E, Graef I. Chronic pulmonary arteritis in Schistosomiasis mansoni associated with right ventricular hypertrophy: report of a case. Am. J. Pathol. 11, 693-706 (1935).
31. Lopes De Fari. Cor pulmonale in Manson's schistosomiasis. I. Frequency in necropsy material; pulmonary vascular changes caused by schistosome ova. Am. J. Pathol. 30, 167-193 (1954).
32. Bouree P, Piveteau J, Gerbal JL, Halpen G. [Pulmonary arterial hypertension due to bilharziasis. Apropos of a case due to Schistosoma haematobium having been cured by praziquantel]. Bull. Soc. Pathol. Exot. 83, 66-71 (1990).
33. De Cavalcanti IL, Tompson G, De Souz, Barbosa FS. Pulmonary hypertension in schistosomiasis. Br. Heart J. 24, 363-371 (1962).
34. Turner PP. Schistosomal pulmonary arterial hypertension in east Africa. Br. Heart J. 26, 821-831 (1964).
35. Lapa MS, Ferreira EV, Jardim C, Martins BC, Arakaki JS, Souza R. [Clinical characteristics of pulmonary hypertension patients in two reference centers in the city of Sao Paulo]. Rev. Assoc. Med. Bras. 52, 139-143 (2006).
36. Humbert M, Sitbon O, Chaouat A et al. Pulmonary arterial hypertension in France: results from a national registry. Am. J. Respir. Crit. Care Med. 173, 1023-1030 (2006).
37. Peacock AJ, Murphy NF, McMurray JJ, Caballero L, Stewart S. An epidemiological study of pulmonary arterial hypertension. Eur. Respir. J. 30, 104-109 (2007).
38. Watt G, Long GW, Calubaquib C, Ranoa CP. Cardiopulmonary involvement rare in severe Schistosoma japonicum infection. Trop. Geogr. Med. 38, 233-239 (1986).
39. Ostrea EM Jr, Marcelo FB Jr. Relationship between pulmonary Schistosomiasis japonicum and cor pulmonale. A pathologic study. Acta Med. Philipp. 2, 68-77 (1965).
40. Ferreira RC, Domingues AL, Bandeira AP et al. Prevalence of pulmonary hypertension in patients with schistosomal liver fbrosis. Ann. Trop. Med. Parasitol. 103, 129-143 (2009).
41. Dorfmuller P, Perros F, Balabanian K, Humbert M. Infammation in pulmonary arterial hypertension. Eur. Respir. J. 22, 358-363 (2003).
42. Hassoun PM, Mouthon L, Barbera JA et al. Infammation, growth factors, and pulmonary vascular remodeling. J. Am. Coll. Cardiol. 54, S10-S19 (2009).
43. Butrous G, Ghofrani HA, Grimminger F. Pulmonary vascular disease in the developing world. Circulation 118, 1758-1766 (2008).
44. Humbert M, Morrell NW, Archer SL et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J. Am. Coll. Cardiol. 43, 13S-24S (2004). (Pubitemid 38759713)
45. Cool CD, Stewart JS, Werahera P et al. Three-dimensional reconstruction of pulmonary arteries in plexiform pulmonary hypertension using cell-specifc markers. Evidence for a dynamic and heterogeneous process of pulmonary endothelial cell growth. Am. J. Pathol. 155, 411-419 (1999).
46. Voelkel NF, Tuder RM. Cellular and molecular biology of vascular smooth muscle cells in pulmonary hypertension. Pulm. Pharmacol. Ther. 10, 231-241 (1997).
47. de Almeida MA, Andrade ZA. Effect of chemotherapy on experimental pulmonary schistosomiasis. Am. J. Trop. Med. Hyg. 32, 1049-1054 (1983).
48. Hesse M, Piccirillo CA, Belkaid Y et al. The pathogenesis of schistosomiasis is controlled by cooperating IL-10-producing innate effector and regulatory T cells. J. Immunol. 172, 3157-3166 (2004).
49. Byram JE, von Lichtenberg F. Altered schistosome granuloma formation in nude mice. Am. J. Trop. Med. Hyg. 26, 944-956 (1977).
50. Allam G. Immunomodulatory effects of curcumin treatment on murine Schistosomiasis mansoni. Immunobiology 214, 712-727 (2009).
51. Araujo N, Mattos AC, Coelho PM, Katz N. Association of oxamniquine praziquantel and clonazepam in experimental Schistosomiasis mansoni. Mem. Inst. Oswaldo Cruz 103, 781-785 (2008).
52. Casella ML, Fanni VS, Verndl DO, Basso MC, Mello LF, Glina S. Schistosomiasis mansoni of the bladder simulating bladder cancer: a case report. Rev. Soc. Bras. Med. Trop. 42, 581-582 (2009).
53. Chhina MK, Nargues W, Grant GM, Nathan SD. Evaluation of imatinib mesylate in the treatment of pulmonary arterial hypertension. Future Cardiol. 6, 19-35 (2010).
54. Klein M, Schermuly RT, Ellinghaus P et al. Combined tyrosine and serine/threonine kinase inhibition by sorafenib prevents progression of experimental pulmonary hypertension and myocardial remodeling. Circulation 118, 2081-2090 (2008).
55. McMurtry IF, Abe K, Ota H, Fagan KA, Oka M. Rho kinase-mediated vasoconstriction in pulmonary hypertension. Adv. Exp. Med. Biol. 661, 299-308 (2010).
56. Moreno-Vinasco L, Garcia JG. Receptor tyrosine kinase inhibitors in rodent pulmonary hypertension. Adv. Exp. Med. Biol. 661, 419-434 (2010).
57. Fu LJ, Zhou AQ, Shen J, Zhao W, Li F. [Effect of elastase inhibitor on pulmonary hypertension induced by monocrotaline]. Zhonghua Er Ke Za Zhi 42, 375-378 (2004).
58. Schermuly R, Grimminger F. [Update in basic research in the therapy of pulmonary arterial hypertension]. Dtsch. Med. Wochenschr. 133(Suppl. 6) S170-S172(2008).
59. Zaidi SH, You XM, Ciura S, Husain M, Rabinovitch M. Overexpression of the serine elastase inhibitor elafn protects transgenic mice from hypoxic pulmonary hypertension. Circulation 105, 516-521 (2002).
60. Murray F, Patel HH, Suda RY et al. Expression and activity of cAMP phosphodiesterase isoforms in pulmonary artery smooth muscle cells from patients with pulmonary hypertension: role for PDE1. Am. J. Physiol. Lung Cell Mol. Physiol. 292, L294-L303 (2007).
61. Schermuly RT, Pullamsetti SS, Kwapiszewska G et al. Phosphodiesterase 1 upregulation in pulmonary arterial hypertension: target for reverse-remodeling therapy. Circulation 115, 2331-2339 (2007).
62. Janssen W, Ghofrani HA, Weissmann N, Grimminger F, Schermuly RT. [Update: preclinical developments for the treatment of pulmonary arterial hypertension]. Dtsch. Med. Wochenschr. 134 (Suppl. 5) S157-S159 (2009).
63. Lambertucci JR, Serufo JC, Gerspacher-Lara R et al. Schistosoma mansoni: assessment of morbidity before and after control. Acta Trop. 77, 101-109 (2000).
64. Guazzi M, Vicenzi M, Samaja M. [Clinical use of phosphodiesterase-5 inhibitors in cardiopulmonary diseases: from experimental evidence to clinical application]. G. Ital. Cardiol. (Rome) 10, 725-737 (2009).
65. Singh TP. Clinical use of sildenafl in pulmonary artery hypertension. Expert Rev. Respir. Med. 4, 13-19 (2010).
66. Grimminger F, Schermuly RT. PDGF receptor and its antagonists: role in treatment of PAH. Adv. Exp. Med. Biol. 661, 435-446 (2010).